Drug Profile
Adalimumab biosimilar - Zydus Cadila
Alternative Names: Adaly; Exemptia; ZRC-3197Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Developer Glenmark Pharmaceuticals Ltd; Zydus Cadila
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 31 Jan 2020 Cadila Healthcare completes a phase I pharmacokinetics trial in Healthy volunteers in India, before January 2020 (CTRI/2019/01/017346)
- 25 Sep 2019 Cadila Healthcare plans a phase I pharmacokinetics trial in Healthy volunteers in India (CTRI/2019/01/017346)
- 26 Feb 2018 Ligand Pharmaceuticals, prior to February 2018, acquires the economic rights to the adalimumab biosimilar programme that utilises the SUREtechnology platform